FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162273192> ?p ?o ?g. }

• W2162273192 endingPage "1134" @default.
• W2162273192 startingPage "1129" @default.
• W2162273192 abstract "To present our experience of high-dose interleukin-2 (HDIL-2) in a high-volume National Cancer Institute-designated center for patients with metastatic renal cell carcinoma (mRCC).Patients with mRCC who received HDIL-2 monotherapy as a first- or second-line therapy during 2004-2011 were identified. Demographics, pathologic variables, renal function, time until the start of HDIL-2 therapy, number of cycles (1-3), responses (complete response, partial response, stable disease, and progressive disease), and primary renal cell carcinoma treatment were analyzed. Progression-free survival and overall survival (OS) were determined.Of 906 patients in the kidney cancer database, 91 patients with mRCC were treated with HDIL-2 and 18 patients (20.5%) underwent prior cytoreductive nephrectomy. Median age was 51 years, and 73.9% were men. Median follow-up was 45 months. Pretreatment renal function impairment led to more treatment cycles (2-3) than in those with adequate initial kidney function (92.3% vs 50.6%, respectively; P = .002). Lower tumor stage correlated with a better response (P = .023) and with longer time from diagnosis to initiation of HDIL-2 (P = .011). Complications included hypotension (67.4%), renal impairment (63%), impaired liver function (42.4%), and thrombocytopenia (31.5%). Four patients (4.5%) had a complete response, 10 (11.4%) had a partial response, and 28 (31.8%) had a stable disease. Median progression-free survival and OS were 8.6 and 35.5 months, respectively. The estimated 2-year OS rate was 60.6%.Incorporating HDIL-2 therapy in the treatment strategies for mRCC added to the patients' survival in this series. HDIL-2 therapy is well tolerated in patients with pre-existing renal impairment with no long-term renal toxicity." @default.
• W2162273192 created "2016-06-24" @default.
• W2162273192 creator A5001550474 @default.
• W2162273192 creator A5003107448 @default.
• W2162273192 creator A5005308056 @default.
• W2162273192 creator A5011054139 @default.
• W2162273192 creator A5017337096 @default.
• W2162273192 creator A5033590637 @default.
• W2162273192 creator A5034313542 @default.
• W2162273192 creator A5034840908 @default.
• W2162273192 creator A5041236048 @default.
• W2162273192 creator A5048141292 @default.
• W2162273192 creator A5050141964 @default.
• W2162273192 creator A5054137912 @default.
• W2162273192 creator A5058902095 @default.
• W2162273192 creator A5075656682 @default.
• W2162273192 creator A5039476274 @default.
• W2162273192 date "2014-05-01" @default.
• W2162273192 modified "2023-09-27" @default.
• W2162273192 title "High-dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma: A Contemporary Experience" @default.
• W2162273192 cites W1487317674 @default.
• W2162273192 cites W1914396593 @default.
• W2162273192 cites W1983365569 @default.
• W2162273192 cites W1984521423 @default.
• W2162273192 cites W1987446429 @default.
• W2162273192 cites W1992732721 @default.
• W2162273192 cites W2012951244 @default.
• W2162273192 cites W2019607817 @default.
• W2162273192 cites W2030709723 @default.
• W2162273192 cites W2046507292 @default.
• W2162273192 cites W2080679809 @default.
• W2162273192 cites W2082331198 @default.
• W2162273192 cites W2123914905 @default.
• W2162273192 cites W2135139265 @default.
• W2162273192 cites W2139248078 @default.
• W2162273192 cites W2161787520 @default.
• W2162273192 cites W2171469612 @default.
• W2162273192 cites W2173123780 @default.
• W2162273192 cites W2181582784 @default.
• W2162273192 cites W2260176825 @default.
• W2162273192 cites W2322647426 @default.
• W2162273192 cites W2334694951 @default.
• W2162273192 doi "https://doi.org/10.1016/j.urology.2014.02.005" @default.
• W2162273192 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24767525" @default.
• W2162273192 hasPublicationYear "2014" @default.
• W2162273192 type Work @default.
• W2162273192 sameAs 2162273192 @default.
• W2162273192 citedByCount "22" @default.
• W2162273192 countsByYear W21622731922014 @default.
• W2162273192 countsByYear W21622731922015 @default.
• W2162273192 countsByYear W21622731922016 @default.
• W2162273192 countsByYear W21622731922017 @default.
• W2162273192 countsByYear W21622731922018 @default.
• W2162273192 countsByYear W21622731922019 @default.
• W2162273192 countsByYear W21622731922020 @default.
• W2162273192 countsByYear W21622731922023 @default.
• W2162273192 crossrefType "journal-article" @default.
• W2162273192 hasAuthorship W2162273192A5001550474 @default.
• W2162273192 hasAuthorship W2162273192A5003107448 @default.
• W2162273192 hasAuthorship W2162273192A5005308056 @default.
• W2162273192 hasAuthorship W2162273192A5011054139 @default.
• W2162273192 hasAuthorship W2162273192A5017337096 @default.
• W2162273192 hasAuthorship W2162273192A5033590637 @default.
• W2162273192 hasAuthorship W2162273192A5034313542 @default.
• W2162273192 hasAuthorship W2162273192A5034840908 @default.
• W2162273192 hasAuthorship W2162273192A5039476274 @default.
• W2162273192 hasAuthorship W2162273192A5041236048 @default.
• W2162273192 hasAuthorship W2162273192A5048141292 @default.
• W2162273192 hasAuthorship W2162273192A5050141964 @default.
• W2162273192 hasAuthorship W2162273192A5054137912 @default.
• W2162273192 hasAuthorship W2162273192A5058902095 @default.
• W2162273192 hasAuthorship W2162273192A5075656682 @default.
• W2162273192 hasConcept C121608353 @default.
• W2162273192 hasConcept C126322002 @default.
• W2162273192 hasConcept C126894567 @default.
• W2162273192 hasConcept C141071460 @default.
• W2162273192 hasConcept C143998085 @default.
• W2162273192 hasConcept C146357865 @default.
• W2162273192 hasConcept C151730666 @default.
• W2162273192 hasConcept C159641895 @default.
• W2162273192 hasConcept C2777472916 @default.
• W2162273192 hasConcept C2777546739 @default.
• W2162273192 hasConcept C2778653478 @default.
• W2162273192 hasConcept C2778822529 @default.
• W2162273192 hasConcept C2779134260 @default.
• W2162273192 hasConcept C2780091579 @default.
• W2162273192 hasConcept C2780227381 @default.
• W2162273192 hasConcept C2781068499 @default.
• W2162273192 hasConcept C71924100 @default.
• W2162273192 hasConcept C86803240 @default.
• W2162273192 hasConcept C90924648 @default.
• W2162273192 hasConceptScore W2162273192C121608353 @default.
• W2162273192 hasConceptScore W2162273192C126322002 @default.
• W2162273192 hasConceptScore W2162273192C126894567 @default.
• W2162273192 hasConceptScore W2162273192C141071460 @default.
• W2162273192 hasConceptScore W2162273192C143998085 @default.
• W2162273192 hasConceptScore W2162273192C146357865 @default.
• W2162273192 hasConceptScore W2162273192C151730666 @default.

• next